FII, DII data: FPIs bought shares worth Rs 722 cr, DIIs added shares worth Rs 2406 cr on August 16, Wednesday Foreign institutional investors (FII) bought shares worth net Rs 722.76 crore, while domestic institutional investors (DII) added shares worth net Rs 2,406.19 crore on August 16, 2023, according to the provisional data available on the NSE. For the month till August 16, 2023, FIIs sold shares worth net Rs 9,148 crore while DIIs bought shares worth net Rs 9,220.65 crore. In the month of July, FIIs bought shares worth net Rs 13,922.01 crore while DIIs sold equities worth net Rs 1,184.33 crore. On Wednesday, domestic indices ended in the green. The NSE Nifty 50 rose 30.45 points or 0.16% to 19,465 and BSE Sensex climbed 137.50 points or 0.21% to 65,539.42. In sectoral indices, Bank Nifty plunged 0.33%, Nifty Financial Services tumbled 0.34%, Nifty Private Bank fell 0.46%, and Nifty Metal tanked 0.94%, while Nifty Media soared 1.20%, Nifty FMCG rose 0.41%, Nifty IT gained 0.59%, and Nifty Pharma climbed 0.61%. The top gainers on Nifty 50 were Apollo Hospital Enterprises, Ultratech Cement, NTPC, Infosys and Tata Motors, while the top losers were Tata Steel, Adani Ports, Hindalco Industries, HDFC Life Insurance and Bharti Airtel. Foreign institutional investors (FII) or Foreign portfolio investors (FPI) are those who invest in the financial assets of a country while not being part of it. On the other hand, domestic institutional investors (DII), as the name suggests, invest in the country they’re living in. Political and economic trends impact the investment decisions of both FIIs and DIIs. Additionally, both types of investors – foreign institutional investors (FIIs) and domestic institutional investors (DIIs) – can impact the economy’s net investment flows.
Services miss estimates; Software better than expected: Services business grew 0.6% q-o-q cc and missed HCLT’s Q3FY23 guidance, mainly due to a 3.8% q-o-q cc decline in the ER&D segment. Growth in the IT&BS segment moderated slightly to 1.6% q-o-qcc but was in line with estimates. BFSI and Life Sciences were the key growth drivers, while communications were the drag among verticals. Growth was led by the Americas region, while Europe and ROW posted declines.
Decline in bookings reflects delays in decision-making: HCLT won 10 large deals in services and three large deals in Software with net-new deal TCV of $2.1bn, down 8% y-o-y. Deal wins were driven by the services portfolio, were centered on cost optimisation and vendor consolidation and came mainly from BFSI, manufacturing and Life Sciences verticals. Management highlighted a ramp-down in discretionary spending in Hitech and communications verticals but pointed to a strong deal pipeline.
FY24 guidance in line with expectations: HCLT has guided for 6-8% y-o-y growth for overall business and 6.5-8.5% y-o-y cc growth in services segment and 18-19% margins in FY24—all in line with our assumptions. We maintain our FY24-25 cc revenue growth and margin estimates and expect HCLT to deliver 6.5% cc revenue growth and 18.4% margins in FY24. However, we lower our earnings forecasts by 2% to factor the higher tax rate indicated by the management.
Also read: MSME listing: How to migrate from NSE SME platform to main board? Check revised criteria
Raise PT: HCLT has fared better in Q4, particularly in North America and BFSI, unlike its peers. However, rising demand uncertainty as a US recession nears remains a concern. HCLT’s stock at CMP trades at 17x PE and offers a 5% yield, which in our view should limit downsides and derating. Hence, we raise our target PE to 17x (16x earlier) and raise our PT to Rs 1,125, offering 8% potential upside.